Lung ultrasound is a promising screening tool to rule out interstitial lung disease in patients with rheumatoid arthritis
Respirology · 2024-07 · 29 (7) · 588-595
DOI: 10.1111/resp.14679 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respirology, online erschienen am 18.02.2024. Verfasst von M Otaola und 10 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Rehabilitacion Psicofisica de Buenos Aires-Ciudad Autónoma Buenos Aires, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Arthritis, Rheumatoid, Ultrasonography, Lung. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Pfizer.
Abstract (Originalsprache)
Background and Objective It is still controversial how to screen for interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA). We aimed to evaluate the performance of lung ultrasound (LUS) as a screening tool for RA‐ILD and to compare it with the performance of chest auscultation, chest x‐ray and pulmonary function tests (PFTs).
Methods
Cross‐sectional study of consecutive RA patients evaluated at a Rheumatology Clinic in Buenos Aires between January and December 2022. High‐resolution computed tomography (HRCT) was the gold standard for diagnosing ILD and was performed within 30 days of the LUS, chest x‐ray and PFTs. Investigators were blinded to HRCT results and patients' clinical data. LUS was performed by exploring 14 areas and was considered positive when the sum of B lines was ≥5. Performance for the diagnosis of ILD was reported for each diagnostic test.
Results
One hundred and six patients were included; 87 (82%) were women. Median age was 60.9 (±9.5) years‐old. A total of 32 (30.2%, 95% CI: 21.6%–39.9%) had ILD. The sensitivity and negative predictive value of LUS were 90.6% (95% CI 75.0%–98.0%) and 94.7% (95% CI 85.4%–98.9%), respectively. LUS performance was superior to that of the other evaluated diagnostic tests for screening ILD.
Conclusions
Given that the US is a low‐cost point‐of‐care tool with a high negative predictive value, it is emerging as a valuable tool for ruling out ILD in patients with RA. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto de Rehabilitacion Psicofisica de Buenos Aires-Ciudad Autónoma Buenos Aires, Buenos Aires, Argentina.
- Hospital Fernandez-Ciudad Autónoma Buenos Aires, Buenos Aires, Argentina.
- Centro de Diagnóstico Rossi-Ciudad Autónoma Buenos Aires, Buenos Aires, Argentina.
- Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
ORCID-Profile: M Otaola
Förderung
- Pfizer
Zitieren
APA
Otaola, M., Paulin, F., Rosemffet, M., Balcazar, J., Perandones, M., Orausclio, P., Cazenave, T., Rossi, S., Marciano, S., Schneeberger, E., & Citera, G. (2024). Lung ultrasound is a promising screening tool to rule out interstitial lung disease in patients with rheumatoid arthritis. Respirology, 29(7), 588-595. https://doi.org/10.1111/resp.14679
Vancouver
Otaola M, Paulin F, Rosemffet M, Balcazar J, Perandones M, Orausclio P, et al. Lung ultrasound is a promising screening tool to rule out interstitial lung disease in patients with rheumatoid arthritis. Respirology. 2024;29(7):588-595. doi:10.1111/resp.14679
BibTeX
@article{Otaola2024,
author = {Otaola, M and Paulin, F and Rosemffet, M and Balcazar, J and Perandones, M and Orausclio, P and Cazenave, T and Rossi, S and Marciano, S and Schneeberger, E and Citera, G},
title = {Lung ultrasound is a promising screening tool to rule out interstitial lung disease in patients with rheumatoid arthritis},
journal = {Respirology},
year = {2024},
volume = {29},
number = {7},
pages = {588--595},
doi = {10.1111/resp.14679}
}
EUVIMED